Aclaris Therapeutics Inc (ACRS) — Cash Flow-to-Debt Ratio
Aclaris Therapeutics Inc (ACRS) has a Cash Flow-to-Debt Ratio of -0.20x as of September 2025, meaning its operating cash flow of $-10.93 Million could theoretically repay 0% of its total liabilities ($55.43 Million) in one year. See ACRS free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aclaris Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Aclaris Therapeutics Inc across 12 annual periods. Also explore net asset momentum of Aclaris Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aclaris Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Aclaris Therapeutics Inc. For market capitalisation and broader financial context, see how much is Aclaris Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-20.07 Million | $64.77 Million | ▲ +84.1% |
| 2023 | -1.95x | $-78.33 Million | $40.23 Million | ▼ -64.2% |
| 2022 | -1.19x | $-67.57 Million | $56.98 Million | ▼ -22.5% |
| 2021 | -0.97x | $-52.13 Million | $53.87 Million | ▲ +17.0% |
| 2020 | -1.17x | $-38.63 Million | $33.13 Million | ▲ +65.7% |
| 2019 | -3.40x | $-96.44 Million | $28.39 Million | ▼ -103.7% |
| 2018 | -1.67x | $-100.81 Million | $60.44 Million | ▲ +44.3% |
| 2017 | -3.00x | $-54.66 Million | $18.25 Million | ▲ +42.9% |
| 2016 | -5.25x | $-34.60 Million | $6.59 Million | ▲ +59.9% |
| 2015 | -13.10x | $-20.37 Million | $1.55 Million | ▼ -6441.3% |
| 2014 | -0.20x | $-7.64 Million | $38.13 Million | ▲ +4.9% |
| 2013 | -0.21x | $-4.92 Million | $23.37 Million | — |